E. Ohman J or Asset Management AB Raises Holdings in RadNet, Inc. $RDNT

E. Ohman J or Asset Management AB grew its position in RadNet, Inc. (NASDAQ:RDNT) by 1,144.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 452,966 shares of the medical research company’s stock after acquiring an additional 416,563 shares during the period. E. Ohman J or Asset Management AB’s holdings in RadNet were worth $27,934,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of RDNT. Geneos Wealth Management Inc. purchased a new position in shares of RadNet in the 4th quarter valued at about $25,000. Allworth Financial LP boosted its position in RadNet by 346.6% during the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock worth $30,000 after purchasing an additional 305 shares in the last quarter. Danske Bank A S purchased a new position in RadNet during the third quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in RadNet in the fourth quarter valued at approximately $36,000. Finally, Harbour Investments Inc. purchased a new stake in shares of RadNet in the fourth quarter valued at approximately $42,000. 77.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RDNT. Barclays decreased their target price on RadNet from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 20th. Weiss Ratings cut shares of RadNet from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, May 12th. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Finally, Zacks Research downgraded shares of RadNet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $87.43.

RadNet Stock Up 6.8%

Shares of NASDAQ RDNT opened at $77.28 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.79. The business’s 50 day moving average is $61.44 and its two-hundred day moving average is $61.71. RadNet, Inc. has a 52-week low of $50.82 and a 52-week high of $85.84. The firm has a market cap of $6.08 billion, a price-to-earnings ratio of -429.31 and a beta of 1.36.

RadNet (NASDAQ:RDNT) last issued its quarterly earnings data on Sunday, August 9th. The medical research company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.10. The business had revenue of $622.72 million during the quarter, compared to analysts’ expectations of $610.87 million. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The company’s revenue was up 25.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.31 earnings per share. Research analysts predict that RadNet, Inc. will post 0.52 EPS for the current year.

Insider Activity at RadNet

In related news, CEO Cornelis Wesdorp sold 4,750 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total transaction of $276,022.50. Following the sale, the chief executive officer directly owned 69,075 shares of the company’s stock, valued at $4,013,948.25. This represents a 6.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David L. Swartz sold 2,699 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $53.89, for a total transaction of $145,449.11. Following the sale, the director owned 177,013 shares in the company, valued at approximately $9,539,230.57. This trade represents a 1.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 5.14% of the company’s stock.

Trending Headlines about RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: Q2 results exceeded expectations: Adjusted earnings per share was $0.29 versus the $0.20 consensus estimate, while revenue rose 25% year over year to a record $622.7 million, above estimates of $610.9 million. RadNet Q2 earnings results
• Positive Sentiment: Strong imaging demand supported growth: Aggregate MRI, CT and PET/CT procedures increased 21.2%, while same-center advanced imaging volume rose 9.6%. Advanced imaging represented 29.9% of total procedures, helping lift the Imaging Center segment’s adjusted EBITDA margin to 16.1%. RadNet second-quarter financial results
• Positive Sentiment: Digital Health momentum accelerated: Segment revenue increased 56.5% to $32.4 million, and annual recurring revenue nearly doubled to $105.5 million. RadNet also cited approximately $21 million in new second-quarter contract value and a recently FDA-cleared breast-ultrasound AI solution. RadNet strong Q2 results
• Positive Sentiment: 2026 outlook was raised: RadNet increased Imaging Center revenue guidance to $2.37 billion-$2.42 billion, adjusted EBITDA guidance to $345 million-$358 million and free-cash-flow guidance to $115 million-$125 million. RadNet Q2 earnings call transcript
• Negative Sentiment: Profitability remained mixed: Adjusted EPS declined from $0.34 a year earlier to $0.29, and GAAP net income attributable to shareholders fell to $7.5 million from $14.5 million. Digital Health adjusted EBITDA also declined 27.2% as RadNet invested in infrastructure, sales and implementation capabilities.

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.